organic papers

Acta Crystallographica Section E Structure Reports Online

ISSN 1600-5368

Viktor Vrábel,^a* Jozef Kožíšek^b and Štefan Marchalín^c

^aDepartment of Analytical Chemistry, Faculty of Chemical Technology, Slovak Technical University, Radlinskeho 9, Bratislava 81237, Slovak Republic, ^bDepartment of Physical Chemistry, Faculty of Chemical Technology, Slovak Technical University, Radlinskeho 9, Bratislava 81237, Slovak Republic, and ^cDepartment of Organic Chemistry, Faculty of Chemical Technology, Slovak Technical University, Radlinskeho 9, Bratislava 81237, Slovak Republic

Correspondence e-mail: vrabel@cvt.stuba.sk

Key indicators

Single-crystal X-ray study T = 293 KMean $\sigma(C-C) = 0.004 \text{ Å}$ R factor = 0.055 wR factor = 0.125 Data-to-parameter ratio = 21.6

For details of how these key indicators were automatically derived from the article, see http://journals.iucr.org/e.

Diethyl 2-methyl-6-(2-thiazolidinyl)-4-(2-thienyl)-1,4-dihydropyridine-3,5dicarboxylate

In the title compound, $C_{19}H_{24}N_2O_4S_2$, the substituted 1,4dihydropyridine ring has a flat-boat conformation. The two ethoxycarbonyl groups are twisted in the same direction and the plane of the 2-thiophene ring is almost perpendicular to the 1,4-dihydropyridine ring.

Comment

1,4-Dihydropyridine (DHP) derivatives constitute a major class of calcium antagonists and have been a target of structure-activity relationship studies. Several crystallographic studies have correlated the pharmacological effects with the degree of puckering of DHP rings. Triggle and co-workers (Triggle *et al.*, 1980; Fossheim *et al.*, 1982; Janis & Triggle, 1983; Langs & Triggle, 1985) have identified some important structural requirements for biological activity which include: (*a*) the structural integrity of the DHP ring, (*b*) no substitution on the N atom at position 1, (*c*) the 2,6-positions to have alkyl substituents and the 3,5-positions to have ester substituents, (*d*) an aryl substituent at the 4 position of the DHP ring. We have studied the crystal structure of the title compound, (I), and present its structure here.



The molecular structure of (I) is shown in Fig. 1. The shortest intermolecular contact of 3.206(3) Å is for N12...O13(-x, -y + 2, -z). The 1,4-DHP ring has a flat-boat conformation, with atoms N1 and C4 displaced by 0.180 (2) and 0.415 (3) Å, respectively, from the base of the boat. The 2-thiophene ring is nearly planar and is approximately perpendicular to the 1,4-DHP ring [dihedral angle 79.5 (1)°]. The 2-thiazolidine ring is twisted from the mean plane of the central 1,4-DHP mean plane by 56.4 (1)°. Both ester groups have *cis,cis* geometry with respect to the ring double bonds and are rotated slightly out of the 1,4-DHP plane, with a C6–C5–C22–O24 torsion angle of 177.3 (2)° and a C2–C3–C12–O14 torsion angle of $-171.5(2)^\circ$.

Experimental

 \odot 2003 International Union of Crystallography Printed in Great Britain – all rights reserved

The title compound, (I), was prepared by a condensation reaction of the starting diethyl 2-formyl-6-methyl-(2-thienyl)-1,4-dihydroReceived 17 February 2003 Accepted 20 February 2003

Online 28 February 2003

pyridine-3,5-dicarboxylate (Marchalín *et al.*, 2001) with 2-aminoethanethiol. Yellow prismatic crystals of (I) were prepared by recrystallization from an ethanol solution.

 $D_m = 1.33 (1) \text{ Mg m}^{-3}$

bromoform-hexane

Cell parameters from 6596

Mo $K\alpha$ radiation

reflections

 $\theta=12.4{-}28.6^\circ$

 $\mu = 0.29 \text{ mm}^{-1}$

T = 293 (2) K

Prism, yellow

 $0.4 \times 0.3 \times 0.2 \text{ mm}$

 D_m measured by flotation in

Crystal data

 $\begin{array}{l} C_{19}H_{24}N_2O_4S_2\\ M_r = 408.52\\ \text{Triclinic, } P\overline{1}\\ a = 8.9441 \ (18) \ \mathring{A}\\ b = 11.222 \ (2) \ \mathring{A}\\ c = 11.489 \ (2) \ \mathring{A}\\ \alpha = 69.21 \ (3)^{\circ}\\ \beta = 71.47 \ (3)^{\circ}\\ \gamma = 83.99 \ (3)^{\circ}\\ V = 1022.0 \ (4) \ \mathring{A}^3\\ Z = 2\\ D_x = 1.327 \ \text{Mg m}^{-3} \end{array}$

Data collection

Oxford Diffraction Xcalibur CCD	2163 reflections with $I > 2\sigma(I)$
diffractometer	$R_{\rm int} = 0.032$
ω and φ scans	$\theta_{\rm max} = 29.1^{\circ}$
Absorption correction: none	$h = -10 \rightarrow 12$
6596 measured reflections	$k = -15 \rightarrow 15$
5344 independent reflections	$l = -15 \rightarrow 15$
•	

Refinement

Refinement on F^2	H-atom parameters constrained		
$R[F^2 > 2\sigma(F^2)] = 0.055$	$w = 1/[\sigma^2(F_o^2) + (0.0448P)^2]$		
$wR(F^2) = 0.125$	where $P = (F_o^2 + 2F_c^2)/3$		
S = 0.96	$(\Delta/\sigma)_{\rm max} = 0.022$		
5344 reflections	$\Delta \rho_{\rm max} = 0.46 \text{ e } \text{\AA}^{-3}$		
247 parameters	$\Delta \rho_{\rm min} = -0.48 \text{ e } \text{\AA}^{-3}$		

Table 1

Selected geometric parameters (Å, °).

C2-C3	1.346 (3)	C7-N12	1.439 (3)
C2-C7	1.517 (3)	C7-S8	1.861 (2)
C3-C4	1.517 (3)	C9-S8	1.806 (3)
C4-C17	1.524 (3)	C12-O13	1.204 (3)
C4-C5	1.527 (3)	C17-S18	1.717 (3)
C5-C6	1.343 (4)	C22-O23	1.205 (3)
C3-C2-N1	119.4 (2)	O23-C22-O24	121.8 (3)
C3-C4-C17	109.44 (19)	C2-N1-C6	122.3 (2)
C3-C4-C5	109.8 (2)	C9-S8-C7	92.38 (13)
C7-N12-C10	111.0(2)	C19-S18-C17	92.42 (15)
O13-C12-O14	121.7 (2)		
C7-C2-C3-C4	169.4 (2)	C2-C3-C12-O14	-171.5 (2)
C2-C3-C4-C17	-89.3(3)	C4-C5-C22-O23	171.9 (3)
C2-C3-C4-C5	34.2 (3)	C6-C5-C22-O24	177.3 (2)
C17-C4-C5-C6	90.9 (3)	C7-C2-N1-C6	161.5 (2)
\$8-C7-N12-C10	-25.0(2)	C5-C6-N1-C2	20.1 (3)
C4-C3-C12-O13	-170.6 (2)	C10-C9-S8-C7	20.1 (2)

Table 2

Hydrogen-bonding geometry (Å, °).

$D-\mathrm{H}\cdots A$	D-H	$H \cdot \cdot \cdot A$	$D{\cdots}A$	$D - H \cdot \cdot \cdot A$
N1-H1···N12	0.86	2.27	2.652 (2)	107



Figure 1

The molecular structure of (I), with the atomic numbering scheme. Displacement ellipsoids are drawn at the 50% probability level.

All H atoms were positioned geometrically and were treated as riding atoms (N–H = 0.86 Å and C–H = 0.93–0.98 Å), with $U_{\rm iso}$ values set at $1.2U_{\rm eq}$ (1.5 $U_{\rm eq}$ for methyl) of the parent atom.

Data collection: *CrysAlisCCD* (Oxford Diffraction Limited, 2002); cell refinement: *CrysAlisRED* (Oxford Diffraction Limited, 2002); data reduction: *CrysAlisRED*; program(s) used to solve structure: *SHELXS*97 (Sheldrick, 1997); program(s) used to refine structure: *SHELXL*97 (Sheldrick, 1997); molecular graphics: *DIAMOND* (Brandenburg, 2001); software used to prepare material for publication: *SHELXL*97.

This work was supported by the Grant Agency of the Slovak Republic (grant Nos. 1/9249/02 and 1/9255/02).

References

- Brandenburg, K. (2001). *DIAMOND*. Version 2.1e. Crystal Impact GbR, Bonn, Germany.
- Fossheim, R., Svarteng, K., Mostagd, A., Romming, C., Shefter, E. & Triggle, D. J. (1982). J. Med. Chem. 25, 126–131.
- Janis, R. A. & Triggle, D. J. (1983). J. Med. Chem. 26, 775-785.
- Langs, D. A. & Triggle, D. J. (1985). Mol. Pharmacol. 27, 544-548.
- Marchalín, S., Chudík, M., Cvopová, K., Pham-Huu, P., Kožíšek, J., Svoboda, I. & Daich, A. (2001). *Tetrahedron Lett.* 42, 5663–5667.
- Oxford Diffraction Limited (2002). CrysAlisCCD and CrysAlisRED. Oxford Diffraction Ltd, Köln, Germany.

Sheldrick, G. M. (1997). SHELXL97 and SHELXS97. University of Göttingen, Germany.

Triggle, A. M., Shefter, E. & Triggle, D. J. (1980). J. Med. Chem. 23, 1442-1445.